Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer
NCT ID: NCT00657904
Last Updated: 2012-06-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
3618 participants
INTERVENTIONAL
1995-08-31
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer
NCT00673205
Casodex vs Placebo in Non-Metastatic Early Prostate Cancer
NCT00672282
Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer
NCT00636259
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
NCT00470834
Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer
NCT00659438
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Bicalutamide
150mg daily
2
Placebo
once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bicalutamide
150mg daily
Placebo
once daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Prostate removed and/or radiation therapy to the prostate area
Exclusion Criteria
* Previous history of another form of cancer (not prostate) within 5 years of study start.
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
William See
Role: PRINCIPAL_INVESTIGATOR
Medical College of Wisconsin
David G. McLeod
Role: PRINCIPAL_INVESTIGATOR
Walter Reed Army Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Birmingham, Alabama, United States
Research Site
Mobile, Alabama, United States
Research Site
Scottsdale, Arizona, United States
Research Site
Tucson, Arizona, United States
Research Site
Berkeley, California, United States
Research Site
Laguna Woods, California, United States
Research Site
Newport Beach, California, United States
Research Site
San Diego, California, United States
Research Site
San Francisco, California, United States
Research Site
Santa Monica, California, United States
Research Site
Thousand Oaks, California, United States
Research Site
Torrance, California, United States
Research Site
Van Nuys, California, United States
Research Site
Denver, Colorado, United States
Research Site
Middlebury, Connecticut, United States
Research Site
New Haven, Connecticut, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Aventura, Florida, United States
Research Site
Bay Pines, Florida, United States
Research Site
Boca Raton, Florida, United States
Research Site
Daytona Beach, Florida, United States
Research Site
Fort Myers, Florida, United States
Research Site
Gainesville, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Ocala, Florida, United States
Research Site
Saint Augustine, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
Chicago, Illinois, United States
Research Site
Fort Wayne, Indiana, United States
Research Site
Greenwood, Indiana, United States
Research Site
Iowa City, Iowa, United States
Research Site
Kansas City, Kansas, United States
Research Site
Louisville, Kentucky, United States
Research Site
Shreveport, Louisiana, United States
Research Site
Greenbelt, Maryland, United States
Research Site
Rockville, Maryland, United States
Research Site
Burlington, Massachusetts, United States
Research Site
Newtown, Massachusetts, United States
Research Site
Ann Arbor, Michigan, United States
Research Site
Detroit, Michigan, United States
Research Site
Rochester, Minnesota, United States
Research Site
Hattiesburg, Mississippi, United States
Research Site
Jackson, Mississippi, United States
Research Site
St Louis, Missouri, United States
Research Site
Omaha, Nebraska, United States
Research Site
Lebanon, New Hampshire, United States
Research Site
Albany, New York, United States
Research Site
Manhasset, New York, United States
Research Site
New York, New York, United States
Research Site
Rochester, New York, United States
Research Site
Syracuse, New York, United States
Research Site
The Bronx, New York, United States
Research Site
Asheville, North Carolina, United States
Research Site
Durham, North Carolina, United States
Research Site
Raleigh, North Carolina, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Portland, Oregon, United States
Research Site
Lancaster, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Cordova, Tennessee, United States
Research Site
Nashville, Tennessee, United States
Research Site
Dallas, Texas, United States
Research Site
Houston, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Salt Lake City, Utah, United States
Research Site
Danville, Virginia, United States
Research Site
Richmond, Virginia, United States
Research Site
Virginia Beach, Virginia, United States
Research Site
Seattle, Washington, United States
Research Site
Madison, Wisconsin, United States
Research Site
Milwaukee, Wisconsin, United States
Research Site
Cheyenne, Wyoming, United States
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Victoria, British Columbia, Canada
Research Site
Winnipeg, Manitoba, Canada
Research Site
Halifax, Nova Scotia, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
Kingston, Ontario, Canada
Research Site
London, Ontario, Canada
Research Site
North York, Ontario, Canada
Research Site
Oakville, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, , Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists' Group. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int. 2010 Apr;105(8):1074-81. doi: 10.1111/j.1464-410X.2010.09319.x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
7054IL/0023
Identifier Type: -
Identifier Source: secondary_id
D6876C00023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.